Entering text into the input field will update the search result below

Amgen Is Not Compelling At The Current Price

May 06, 2021 10:23 PM ETAmgen Inc. (AMGN)18 Comments
Geoff Considine profile picture
Geoff Considine


  • AMGN's valuation is reasonable but the stock is not cheap.
  • The Wall Street consensus rating is bullish but the stock is very close to the consensus 12-month price target.
  • The market-implied outlook is neutral, with moderate volatility.
  • There is high dispersion among the Wall Street analyst price targets.
  • My overall rating is neutral.

Amgen headquarters in Silicon Valley
Photo by Sundry Photography/iStock Editorial via Getty Images

Amgen (NASDAQ:AMGN) is a major pharmaceutical company, with a $142B market cap and $5.9B in revenue for Q1 2021 and expected revenue of $26B for the full year. The company faced substantial

This article was written by

Geoff Considine profile picture
Geoff has worked in quantitative finance for more than twenty years. Before entering finance, Geoff was a research scientist for NASA. Geoff holds a PhD in Atmospheric Science from the University of Colorado - Boulder and a BS in Physics from Georgia Tech. Neither Geoff Considine nor Quantext (Geoff's company) are investment advisors. Nothing in any commentary here on Seeking Alpha or elsewhere shall be regarded as advice.

Analyst’s Disclosure: I am/we are long ABBV. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.